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Summary 
Background Patients with Parkinson's disease have higher hospital admission rates 
than the general population. We examined the reasons for admission, length of stay, 
costs, and in-hospital mortality in a national sample of Parkinson's disease patients. 
Methods We used hospital admission data from the English Hospital Episodes 
Statistics database (2009 to 2013). Patients with Parkinson's disease or Parkinson's 
disease dementia and aged over 35 years were compared to all other admissions, 
excluding the above, with the same age criteria. We examined reasons for 
admissions (ICD-10), length of stay and in-hospital mortality. We used indirect 
standardisation and Poisson modelling to derive proportional ratios adjusting for age 
group and sex. 
Results There were 324,055 Parkinson's disease admissions in 182,859 patients 
over 4 years which included 232,905 non-elective admissions (72%). This resulted in 
expenditure of £907 million (£777 million for non-elective admissions). The main 
reasons for admission were pneumonia (13.5%), motor decline (9.4%), urinary tract 
infection (9.2%), and hip fractures (4.3%). These conditions occurred 1.5 to 2.6 times 
more frequently in patients than controls. Patients with Parkinson's disease were 
almost twice as likely to stay in hospital for more than 3 months (ratio 1.90, 95% CI 
1.83, 1.97) and even more likely die in hospital (ratio 2.46, 95% CI 2.42, 2.49).  
Conclusions Parkinson's disease patients in England have higher rates of 
emergency admissions with longer hospital stays, higher costs and in-hospital 
mortality. Urgent attention should be given to developing cost-effective interventions 
to reduce the burden of hospitalisation for patients, carers and healthcare systems. 
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INTRODUCTION 
With the ageing of the population in developed countries, the number of people 
affected by Parkinson’s disease (PD) will rise[1] with the inevitable dramatic increase 
in healthcare costs of hospitalisation. A greater understanding is required about the 
whole process of hospitalisation in PD patients including why they are admitted, what 
happens during admission, and what happens on discharge. Only then can we 
develop improved processes to prevent or better manage hospitalisation. 
 
Most previous studies have examined PD admissions to individual hospitals,[2-6] 
with relatively small sample sizes. One recent regional study from New South Wales, 
Australia documented the reasons for 5,637 admissions over a 4 year period.[7] The 
largest study came from an administrative database study in Ontario, Canada in 
2003 with 15,304 PD patients. This showed that PD led to increased hospital 
admissions, longer admissions, higher drug costs, and higher physician costs.[8] 
There is a need for an up-to-date examination of PD admissions on a nationwide 
basis to inform healthcare planning. 
 
We have examined the English Hospital Episode Statistics (HES) data on all 
admissions related to PD over a 4 year period to establish the size of the problem, 
the direct healthcare costs of admissions, the reasons why patients were admitted, 
and hospital mortality with the aim of recommending initiatives to reduce the burden 
of PD admissions. 
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METHODS 
Data source  
The HES database contains records including patient admissions, outpatient 
appointments and accident and emergency (A&E) attendances at healthcare 
providers (predominantly hospitals) in English NHS hospitals and English National 
Health Service (NHS) commissioned activity in the independent sector.[9] This 
includes zero bed days (ZBDs), where patients were admitted and discharged within 
24 hours. These data are submitted to allow hospitals to be paid for the services they 
deliver.  
 
For this study, hospital admissions within the HES database between 1st April 2009 
and 31st March 2013 were extracted. The data was anonymised, so the study 
constituted a service evaluation which did not require ethical committee approval. 
Diagnoses were recorded using the International Classification of Diseases, 10th 
Revision (ICD-10). The main reason leading to an admission was coded as the 
primary diagnosis. Only one primary diagnosis was permitted for each admission, 
but up to 19 different secondary diagnoses were allowed. The secondary diagnosis 
was any condition that existed in addition to the primary reason as deemed relevant. 
 
We extracted data on patient count, admission count (finished admission episodes), 
cost of admission, type of admission (elective/non-elective), coded reasons for 
admissions, in-hospital mortality, length of stay (LOS) and stays of greater than three 
months of duration. Average LOS was calculated by dividing total bed days by the 
total number of admissions. ZBDs were excluded from all analyses except original 
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headline rates to avoid skewing of the data and because these short admissions 
have less clinical and economic impact.  
 
Parkinson’s disease patients and controls 
Patients with PD were identified by ICD-10 codes of G20X (Idiopathic PD) or F02.3 
(Dementia in PD) either as a primary or secondary diagnosis. Patients under 35 
years were excluded as PD is rare in this age group and may reflect coding errors. 
The control group consisted of patients with admission codes excluding the ICD-10 
codes G20X and F02.3 in any diagnostic field and fulfilling the same age criteria. 
 
Assigning admissions to a specific ‘HES year’ is complex, as patients may already 
be in-patients at the start of the year or discharged after the end of the year. For all 
analyses, except mortality, patients who began their admission before the study start 
date, but were discharged during the study period, were included (0.3% of total 
admissions), but patients who were not discharged by the study end date were 
excluded (2.0% of total) as cost and LOS can only be calculated within HES for 
completed admissions. 
 
For the mortality analysis, only admissions occurring entirely within the 4 year study 
period were used to ensure the appropriate denominator, (i.e. a patient would have 
to be admitted and discharged or died within the 4 year study period). 
 
Admission costs and excess bed days 
Admission costs were calculated by applying the Healthcare Resource Group (HRG) 
for each inpatient stay to the Payment by Results (PbR) rules, the admission method 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
7 
and other details of the hospital stay. This included HRG unit cost and any payments 
because of unexpectedly long hospital stay, or for any specialist care or additional 
treatments and tests. Prices were drawn from the corresponding year of the PbR 
national tariff. HRGs are standard groupings of clinically similar treatments which use 
common levels of healthcare resource. This method is used by healthcare providers 
to calculate reimbursement within the NHS. Each HRG has a maximum expected 
LOS and any stay in hospital beyond this ‘upper trim point’ is paid on a per day basis 
using a specific excess bed days (EBD) tariff which is different for each HRG. EBDs 
highlight exceptionally long inpatient stays. 
 
Reasons for non-elective admissions 
Common reasons for non-elective admissions for PD patients were identified using 
ICD-10 codes. Where G20X or F02.3 codes were secondary diagnoses, the ICD-10 
codes listed as primary diagnosis were examined. Individual ICD-10 codes were 
grouped into larger sub-categories and stratified according to whether they were PD-
related or not, based on the consensus opinion of two clinicians (CEC and RW). 
These were compared with data from the corresponding control group. Admission 
cost and EBD cost for each sub-category were calculated excluding the ‘other’ sub-
category for controls, which proved impractical to calculate given the large numbers.  
 
Statistical analysis 
We present crude and age- and sex-specific descriptive statistics for PD and control 
groups for all admissions and specific diagnostic groups. Ideally, one would then test 
if certain conditions are more likely to result in a higher hospitalisation rate for PD 
patients than controls by calculating the relative admission rate. However, the HES 
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database only contains admission data; it does not provide population denominators. 
Though census data can be used for the control populations, there is no equivalent 
data for PD patients and extrapolating from localised cross-sectional studies may be 
problematic, under-estimating the true population denominator, thereby inflating the 
PD rate. Therefore, we examined the proportion of admissions for a specific cause 
compared to all admissions for PD cases and controls.  Age and sex were taken into 
account, as PD is more common in men and the prevalence increases with age. 
Firstly, we present the PD and control data stratified by age groups and sex allowing 
comparison of age- and sex-specific proportions. Secondly, we used indirect 
standardisation, with proportions in the control population being the standard, so that 
we derived proportional ratios for cause-specific admissions and mortality analogous 
to standardised admission and mortality rates.[10] A ratio >1 indicates a greater 
proportion and a value <1 indicates a lower proportion.  From this, we calculated the 
age- and sex-adjusted admission rate per 100 admissions. Finally, we used Poisson 
regression models using the count of condition-specific admissions as the outcome, 
all admissions as the denominator and an indicator variable for the PD versus control 
groups. We then adjusted for age group and sex in the multivariable models by using 
these as covariates. For LOS, we calculated the mean length for descriptive 
purposes but, because of data skewness, we only formally tested for differences by 
comparing the proportion with a LOS greater than three months (excessive stay) in 
the PD group with controls as above. 
 
RESULTS 
Between 1st April 2009 and 31st March 2013, there were 65,778,094 elective and 
non-elective admissions recorded in HES (Supplementary Figure). Admissions 
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‘under 35’ years of age, ‘unknown’ age or ‘unknown or unspecified sex’ were omitted 
leading to 15,903,994 (24.2%) admissions being excluded. Of the remaining 
49,874,100 admissions, 324,055 were generated by 182,859 PD patients (0.69%) 
and 49,550,045 by 26,419,116 controls almost three times the crude expected 
proportion over 35 years (0.24%) from two recent prevalence studies.[11,12] The 
numbers excluded for reasons other than age <35 years accounted for less than 
0.5% of the total cohort (0.2% of the PD group had missing covariates). 28% and 
72% of PD admissions were elective and non-elective respectively compared to 60% 
and 40% in controls. 
 
Table 1 provides admission count and cost of admissions stratified by sex and age of 
elective and non-elective admissions for PD patients. Approximately 60% of the 
admissions were generated by male patients reflecting the higher male prevalence of 
PD. More admissions occurred in age groups above 65 years of age, with almost 
half of the admissions occurring in 75 to 84 year olds. 
 
The total cost of PD admissions over 4 years was £906,617,908. The cost per 
admission increased with increasing age, with the oldest age bracket (>85 year old) 
costing the most per admission (Table 1). Whilst the proportion of non-elective 
admissions was 72%, the cost was disproportionately higher with non-elective 
admissions resulting in 86% (£777,476,489) of the total cost. The average cost per 
admission reflected this with elective and non-elective admissions costing £1,417 
and £3,338 per admission, respectively. There were no differences in cost per 
admission between male and female patients. 
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After excluding ZBD admissions, the number of non-elective PD admissions was 
204,266 costing £716,606,754 (Table 2). Twelve percent of the total cost consisted 
of EBD costs, incurred due to exceptionally long inpatient stays. The largest category 
was ‘other’ (36.5%), consisting of over 100 ICD-10 codes recorded as a primary 
diagnosis, but appearing at low frequencies. Thereafter, the most common reasons 
for non-elective admissions probably related to PD were pneumonia (13.5%), “PD” 
itself (9.4%), urinary tract infection (UTI; 9.2%), and hip fractures (4.3%). Of these, 
“PD” and hip fracture incurred a higher percentage of the total costs (12% and 7.6% 
respectively) compared to the frequency in which they occurred in relation to the total 
number of admissions. In controls, the proportion of the non-elective admissions for 
pneumonia, UTI and hip fractures of the total were 7%, 2.9% and 1.6% respectively 
(Supplementary Table 1), indicating that these conditions were over-represented in 
patients with PD with unscheduled admissions. 
 
The relative proportions for non-elective admissions between the PD and control 
groups are shown in Supplementary Table 3 for UTI, pneumonia, hip fracture, and 
other fracture. Age and sex-standardised risk and proportional admission ratio have 
been calculated for each condition (Supplementary Tables 2 and 3).  The relative 
proportion of admissions for each of these conditions is substantially higher for each 
condition, especially UTI (ratio 2.63, 95% CI 2.59, 2.67, p<0.0001) with an age and 
sex standardised risk of 6 per 100 admissions.  Pneumonia admissions were more 
common at 8.4 per 100 admissions, but the ratio was less elevated (ratio 1.55, 95% 
CI 1.53, 1.57, p<0.0001) compared to controls. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
11 
Figure 1 shows that mean LOS for non-elective admissions was consistently longer 
in PD patients than controls for both sexes and across all age groups. Mean LOS for 
PD patients was seven days longer than controls (16 versus 9 days). There was a 
trend for increasing mean LOS with increasing age in the PD group which was not 
mirrored in the control group. For the PD group, average LOS between the two 
sexes were comparable, apart from the ‘35 – 44’ year old where LOS for males was 
longer than females. PD patients were almost twice as likely to have admissions 
resulting in LOS greater than three months (ratio 1.90, 95% CI 1.83, 1.97, p<0.0001). 
Mean LOS was longer in PD patients than controls for UTI, pneumonia, hip fracture, 
and other fractures (Supplementary Table 4).  
 
Mortality was increased in PD patients compared with controls (Supplementary 
Table 5) with a proportional mortality ratio of 2.46 (95%CI 2.42, 2.49, p<0.0001). The 
increase was particularly marked for those over 85 years, with around 10% of PD 
admissions resulting in death. 
 
DISCUSSION 
To our knowledge, this is the first study to provide precise national costs of PD 
admissions. Over a 4 year period, there were 324,055 PD admissions at a total cost 
of over £907 million. The vast majority (72%) were non-elective at a cost of £777 
million over 4 years or, on an annual basis, 58,226 admissions costing £194 million. 
Previous studies estimated all aspects of direct healthcare costs in comparison to 
the present study which examined hospital costs only. The 1998 UK Global PD 
Survey (UKGPDS) estimated the annual direct healthcare costs in 432 PD patients 
to be £5,993 per person which suggested a total annual spend on PD of around 
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£600 million at that time.[13] With such large sums, even small reductions in the 
numbers of non-elective admissions would lead to significant savings. 
 
As expected, the admission count and cost per admission increased with age to 
around £3,200 per admission in those over 85 years. Increased co-morbidity in this 
age group may have led to more ‘problems’ being coded which would increase 
costs. Total annual direct healthcare costs also increased with age in the UKGPDS, 
from £3,978 per person less than 65 years to £9,393 per person over 85 years.[13] 
So, interventions focussed on older PD patients should have more financial impact. 
 
Mean LOS for non-elective admissions was seven days longer in PD patients than 
controls. The annual cost of EBDs, relating to exceptionally long inpatient stays, for 
PD emergency admissions was over £22 million highlighting the potential for cost 
savings. Gerlach and colleagues systematic review of PD hospitalisation studies 
found that most previous studies had shown increased LOS in PD.[14] 
 
Most concerning of all is the excess mortality in admitted PD patients compared to 
controls, particularly for those over 85 years, with 10% of PD admissions resulting in  
death. This is consistent with a previous review of case-control and cohort studies 
showing an excess mortality ratio in PD of 2.56 (95% CI 2.46, 2.66, p<0.00001).[15] 
It has been shown that more than 50% of people with PD die in hospital, with nearly 
a third dying in care homes and a much smaller percentage dying at home.[16] This 
calls for improved advance care planning for PD patients with advanced disease. 
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The most frequent reasons for non-elective admissions in our national sample were 
pneumonia (13.5%), advanced “PD” (9.4%), UTI (9.2%), and hip fractures (4.3%). 
This is in line with previous reports from individual institutions,[2-6] although the 
precise proportions differ, probably due to differences in coding. We have also 
shown that UTI, pneumonia, hip fractures and other fractures occur more frequently 
in PD than in age and sex matched controls, with proportional admission ratios from 
1.5 to 2.6 times the control group. Several previous studies have shown an 
increased fracture rate in PD. In a study using the UK General Practice Research 
Database, the risks of any fracture and hip fracture were almost doubled and tripled 
for PD patients (adjusted hazard ratio any fracture 1.89, 95% CI; 1.67, 2.14; risk of 
hip fracture 3.08; 95%, CI 2.43, 3.89).[17] Similarly, using the UK National Hip 
Fracture Database, the relative risk of hip fracture for those aged over 60 years was 
3.7 (95% CI 2.6, 5.3) for PD patients in Northumbria Healthcare NHS Foundation 
Trust in the UK.[18] Imbalance and falls are common in PD and poorly responsive to 
dopaminergic medication. Osteoporosis is common in PD in view of age and 
immobility,[19] so the increased risk of fracture is not surprising. Some of the 
increase of UTI may be due to over-diagnosis of UTI, but bladder function is affected 
in PD.[20] Pneumonia is due to a combination of deteriorating motor function and 
PD-related dysphagia and is a common cause of death.[21] It would seem 
appropriate to focus interventions to reduce admissions on these most common 
causes. 
 
The key issue is to what degree could these admissions, the resulting costs and 
mortality be avoided by better care? We have summarised some potential 
interventions which may reduce and better manage PD non-elective admissions in 
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Table 3.[3, 19, 22-29] The evidence base for some of these interventions is 
speculative and such processes will require careful evaluation before we can 
assume they are cost-effective. Healthcare systems already address some of these 
issues, but we suspect in an ad hoc manner rather than using a systematic 
approach. Different models of healthcare should be considered. For example, PD 
Nurse Specialists could lead an integrated community and secondary care team, 
combining the skills of primary care, hospital specialists, rehabilitation specialists, 
other allied healthcare specialties, and palliative care. 
 
This is the largest study of its kind with real-world direct healthcare costs on which 
reimbursement is based in England. Its main limitation is the reliance on routinely 
coded data with the potential for errors in both coding and costing. However, a 
recent systematic review noted that coding accuracy rates were improving and 
sufficiently robust for both research and managerial decision making.[30] An ongoing 
study examining electronic prescribing records in PD, in addition to the local ICD-10 
returns, at Queen Elizabeth Hospital, Birmingham, UK suggests that ICD-10 returns 
miss over 15% of PD admissions (CEC personal communication). These data would 
suggest we may have under-estimated the size of the problem. We had to calculate 
the proportional risk ratios rather than ratios based on the true PD population at risk. 
This is unlikely to have biased our hospital-based mortality ratios or excessive 
lengths of stay but may have inflated the ratios for urinary tract infections, as PD 
patients are less likely to be admitted with smoking-related morbidity[31] and hence 
other admission causes, if unrelated to smoking, would appear relatively more 
important. However, as smoking predicts fracture risk,[32] then our observed 
estimates for fractures are likely to be an under-estimate. 
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In conclusion, the NHS spends nearly £200 million per year on emergency 
admissions in PD patients. The main reasons for admission are pneumonia, motor 
decline, UTI, and hip fractures which occur more frequently in PD than in a control 
group. PD patients have longer hospital stays and are 2.5 times more likely to die. 
Urgent attention should be given to developing interventions to reduce the burden of 
hospitalisation in PD for patients, their carers and healthcare systems. 
 
 
Acknowledgements 
The authors would like to thank Shahadat Uddin and Rebeka Morley from Health IQ 
for managing and extracting the required data. 
 
Contributors 
V. Low: research project: organisation, and execution; statistical analysis: review and 
critique; manuscript: writing of the first draft, review and critique. 
Y. Ben-Shlomo: research project: organisation, and execution; statistical analysis: 
performance, review and critique; manuscript: review and critique. 
E. Coward: research project: organisation, and execution; manuscript: review and 
critique. 
S. Fletcher: research project: organisation, and execution; manuscript: review and 
critique. 
R. Walker: research project: organisation, and execution; review and critique; 
manuscript: review and critique. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
16 
C.E. Clarke: research project: conception, organisation, and execution; review and 
critique; manuscript: writing of the first draft, review and critique.  
 
Funding 
UCB provided funding to obtain the relevant HES data from HealthIQ. 
 
Competing interests 
C. E. Clarke: Advisory Boards: AbbVie, Britannia, Lundbeck, Teva, UCB; Honoraria: 
AbbVie, Britannia, Lundbeck, Teva, UCB; Educational grants: AbbVie, Britannia, GE 
Healthcare, Lundbeck, Medtronic, Teva. 
R.W. Walker: Advisory Boards: AbbVie, Britannia, Teva; Honoraria: GSK, Lundbeck, 
Teva, UCB. 
V. Low, E. Coward & S. Fletcher are employees of UCB Pharma Ltd. 
 
Ethical approval 
Not required. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
17 
References 
[1] Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. 
Projected number of people with Parkinson disease in the most populous nations, 2005 
through 2030. Neurology. 2007;68:384-6. 
[2] Arasalingam A, Clarke CE. Reasons for Parkinson's disease admissions in a large inner 
city hospital. Parkinsonism Relat Disord. 2014;20:237-8. 
[3] Klein C, Prokhorov T, Miniovitz A, Dobronevsky E, Rabey J. Admission of Parkinsonian 
patients to a neurological ward in a community hospital. J Neural Transm. 
2009;116:1509-12. 
[4] Temlett JA, Thompson PD. Reasons for admission to hospital for Parkinson's disease. 
Intern Med J. 2006;36:524-6. 
[5] Vossius C, Nilsen OB, Larsen JP. Parkinson's disease and hospital admissions: 
frequencies, diagnoses and costs. Acta Neurol Scand. 2010;121:38-43. 
[6] Woodford H, Walker R. Emergency hospital admissions in idiopathic Parkinson's disease. 
Mov Disord. 2005;20:1104-8. 
[7] Lubomski M, Rushworth RL, Tisch S. Hospitalisation and comorbidities in Parkinson's 
disease: a large Australian retrospective study. J Neurol Neurosurg Psychiatry. 2014. 
[8] Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Burden of 
parkinsonism: a population-based study. Mov Disord. 2003;18:313-9. 
[9] Health and social care information centre. Hospital episodes statistics. 2014. 
[10] Rothman K, Greenland S. Modern Epidemiology. Second ed. Philadelphia: Lippincott-
Raven; 1998. 
[11] Porter B, Macfarlane R, Unwin N, Walker R. The prevalence of Parkinson’s disease in 
an area of North Tyneside in the north-east of England. Neuroepidemiology 
2006;26:156–161. 
[12] Wickremaratchi MM, Perera D, O’Loghlen Carl, Sastry D, Morgan E, Jones A, Edwards 
P, Robertson NP, Butler C, Morris HR, Ben-Shlomo Y. Prevalence and age of onset of 
Parkinson’s disease in Cardiff: a community based cross sectional study and meta-
analysis. J Neurol Neurosurg Psychiatry 2009;80:805–807. 
[13] Findley L, Aujla M, Bain PG, Baker M, Beech C, Bowman C, et al. Direct economic 
impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord. 
2003;18:1139-45. 
[14] Gerlach OH, Winogrodzka A, Weber WE. Clinical problems in the hospitalized 
Parkinson's disease patient: systematic review. Mov Disord. 2011;26:197-208. 
[15] Clarke CE. Has drug therapy changed the natural history of Parkinson's disease? J 
Neurol. 2010;257:S262-7. 
[16] Snell K, Pennington S, Lee M, Walker R. The place of death in Parkinson's disease. 
Age Ageing. 2009;38:617-9. 
[17] Pouwels S, Bazelier MT, de Boer A, Weber WE, Neef C, Cooper C, et al. Risk of 
fracture in patients with Parkinson's disease. Osteoporos Int. 2013;24:2283-90. 
[18] Walker RW, Chaplin A, Hancock RL, Rutherford R, Gray WK. Hip fractures in people 
with idiopathic Parkinson's disease: incidence and outcomes. Mov Disord. 2013;28:334-
40. 
[19] van den Bos F, Speelman AD, Samson M, Munneke M, Bloem BR, Verhaar HJ. 
Parkinson's disease and osteoporosis. Age Ageing. 2013;42:156-62. 
[20] Blackett H, Walker R, Wood B. Urinary dysfunction in Parkinson's disease: a review. 
Parkinsonism Relat Disord. 2009;15:81-7. 
[21] Pennington S, Snell K, Lee M, Walker R. The cause of death in idiopathic Parkinson's 
disease. Parkinsonism Relat Disord. 2010;16:434-7. 
[22] Huntley A, Lasserson D, Wye L, Morris R, Checkland K, England H, et al. Which 
features of primary care affect unscheduled secondary care use? A systematic review. 
BMJ Open. 2014;4:e004746. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
18 
[23] Jarman B, Hurwitz B, Cook A. Parkinson's Disease Nurse Specialists in primary care: a 
randomised controlled trial. Mov Disord. 2000;15 (suppl 3):178. 
[24] Tomlinson CL, Patel S, Meek C, Herd CP, Clarke CE, Stowe R, et al. Physiotherapy 
versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev. 
2013;9:CD002817. 
[25] Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with 
Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's 
disease. Cochrane Database Syst Rev. 2012;3:CD006504. 
[26] Herd CP, Tomlinson CL, Deane KH, Brady MC, Smith CH, Sackley CM, et al. Speech 
and language therapy versus placebo or no intervention for speech problems in 
Parkinson's disease. Cochrane Database Syst Rev. 2012;8:CD002812. 
[27] Barber ND, Alldred DP, Raynor DK, Dickinson R, Garfield S, Jesson B, et al. Care 
homes' use of medicines study: prevalence, causes and potential harm of medication 
errors in care homes for older people. Qual Saf Health Care. 2009;18:341-6. 
[28] National Council for Palliative Care. The end of life care strategy: new ambitions. 
London. 2014. 
[29] Skelly R, Brown L, Fakis A, Kimber L, Downes C, Lindop F, et al. Does a specialised 
unit improve outcomes for hospitalised patients with Parkinson's disease. Parkinsonism 
and Related Disorders. 2014. 
[30] Burns EM, Rigby E, Mamidanna R, Bottle A, Aylin P, Ziprin P, et al. Systematic review 
of discharge coding accuracy. J Public Health (Oxf). 2012;34:138-48. 
[31] Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of 
coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol. 
2002;52:276-84. 
[32] Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and 
risk of hip fracture: recognition of a major effect. BMJ. 1997;315:841-6. 
 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
19 
Figure Legend 
Fig 1 Mean length of stay for non-elective admissions for Parkinson's disease and controls (days) 
excluding ZBDs 
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TABLE 1 Admissions and costs for Parkinson's disease patients by age and gender(2009 –2013)* 
 
PD Group 
 Male Female 
Age 
Admission 
count 
% of total 
admissions 
Total cost of 
admissions (£) 
Cost per 
admission 
(£) 
Admission 
count 
% of total 
admissions 
Total cost of 
admissions (£) 
Cost per 
admission 
(£) 
35 – 44 yrs 651 0.3% 1,236,071 1,899 418 0.3% 792,248 1,895 
45 – 54 yrs 3,473 1.8% 6,943,726 1,999 1,774 1.4% 3,401,409 1,917 
55 – 64 yrs 15,658 8.1% 33,014,414 2,108 8,270 6.4% 17,514,879 2,118 
65 – 74 yrs 49,433 25.5% 120,844,023 2,445 28,838 22.2% 72,340,404 2,509 
75 – 84 yrs 87,875 45.3% 251,842,998 2,866 57,855 44.5% 173,343,960 2,996 
> 85 yrs 36,951 19.0% 117,789,799 3,188 32,859 25.3% 107,553,977 3,273 
Total 194,041 100% 531,671,031 2,740 130,014 100% 374,946,877 2,884 
* Patients under 35 yrs/’unknown age’/’unknown sex’/’unspecified sex’ were excluded. Together they comprised of less than 0.2% of the total PD admissions 
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TABLE 2 Reasons for non-elective admissions in PD group excluding ZBDs 
*Recorded as the primary diagnoses 
  
Categories Relation to PD Sub-categories 
Non-elective 
admissions 
Admissions cost (£) 
Excess bed 
day cost (£) 
Parkinson’s Disease 
Probably 
related 
PD* 19,152 85,621,216 15,188,136 
Dementia in PD* 230 110,657 45,066 
Infections 
UTI 18,808 68,253,387 5,011,783 
Pneumonia 27,604 96,232,522 11,176,138 
Septicaemia 1,500 5,427,265 469,479 
Cellulitis 2,132 6,363,726 477,746 
Neuropsychiatric 
disorders 
Senility 5,465 18,495,257 1,093,041 
Disorientation 2,027 6,139,024 511,481 
Delirium 622 513,146 218,947 
Hallucinations 386 54,555 10,108 
Problems relating to 
blood pressure 
Syncope & collapse 4,171 8,577,066 805,168 
Orthostatic hypotension 2,837 7,318,668 1,926,982 
Hypotension 399 975,855 266,833 
Acute renal failure 1,896 7,615,428 532,087 
Volume depletion 1,158 3,750,754 200,602 
Falls & fractures 
Fracture neck of femur 8,775 54,707,957 2,997,913 
Head injuries 2,481 6,786,975 945,367 
Other fractures 2,915 10,784,935 1,826,409 
Gastrointestinal 
disorders 
Constipation 2,428 6,680,518 507,324 
Dysphagia 573 2,092,859 463,742 
Unlikely to be 
related 
Gastroenteritis 2,605 8,709,427 1,323,900 
Nausea & vomiting 634 1,573,621 90,390 
Cardiovascular 
disorders 
Cardiac-related 12,346 30,462,506 2,805,118 
Stroke 3,849 19,041,318 1,397,597 
TIA 1,359 3,487,616 573,848 
Genitourinary & renal 
disorders 
Urinary retention 1,375 3,532,354 276,553 
Complications with catheter 834 2,012,693 177,961 
Haematuria 1,080 2,616,326 194,121 
Other (All other admissions) 74,625 248,669,123 35,411,129 
Total 204,266 716,606,754 86,924,969 
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TABLE 3 Potential interventions to avoid or better manage hospitalisation for PD 
Condition Intervention Evidence base 
Prevention of admission& re-admission  
All Open access to PD nurse service RCT3,23 
 Open access to PD clinic Evidence required 
 Better access to identified general practitioner Systematic review
22 
 Carer support Evidence required 
 Improvement in the process of medicine administration in care homes and better 
communication between care homes and medical personnel (GPs and pharmacists) 
Ethnographic study
27 
Motor decline Medication optimization (if possible) Observational 
evidence 
 Physiotherapy and occupational therapy assessment and possibly treatment Systematic review
24 
Falls and fractures Osteoporosis screening and management Systematic review
19 
Dementia, psychosis Psychiatric assessment, anti-parkinsonian drug reduction, cholinesterase inhibitors Systematic review
25 
Palliative care Consider end-of-life issues Observational 
evidence
28 
Improved management of admission  
All Rapid access to rehabilitation team including physiotherapy, occupational therapy and 
speech and language therapy 
Systematic 
reviews
24,26 
 Access to specialist PD ward Observational 
evidence
29 
 Adequate management for PD patients undergoing surgery Evidence required 
 Alert system to trigger review all PD inpatients by specialist PD team Evidence required 
 Improved access to PD medication in hospitals, especially out-of-hours Evidence required 
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 Swallow assessment and appropriate medicine use in patients with swallowing 
difficulties 
Evidence required 
 Ensure adequate hydration Evidence required 
 Nurse and junior doctor training on the need for PD medication administration on time Evidence required 
 Patient/carer education and empowerment on ensuring that medications are 
conveyed accurately to ward staff together with dose intervals and enquiring on 
possibility of self-medicating 
Evidence required 
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We examined hospitalisation in Parkinson's disease using English Hospital Episodes Statistics. 
There were 324,055 Parkinson's disease admissions in 182,859 patients over 4 years. 
This included 232,905 non-elective admissions which cost £777 million. 
Pneumonia, urinary tract infection and hip fracture occurred 1.5-2.6 times more in patients than 
controls.  
Patients were twice as likely to stay in hospital over 3 months and even more likely die in hospital. 
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SUPPLEMENTARY TABLE 1 Reasons for non-elective admissions in the control group excluding ZBDs 
 
  
Categories Sub-categories 
Non-elective 
admissions 
Admissions 
cost (£) 
Excess bed 
day cost (£) 
Infections 
UTI 457,040 1,308,878,706 86,540,940 
Pneumonia 1,089,265 3,070,321,597 223,970,243 
Septicaemia 69,394 212,360,406 13,805,181 
Cellulitis 148,901 360,375,335 26,849,127 
Neuropsychiatric 
disorders 
Senility 95,260 283,787,111 17,654,524 
Disorientation 58,183 145,864,809 16,641,607 
Delirium 15,340 7,672,104 2,172,521 
Hallucinations 2,183 297,864 61,139 
Problems relating to 
blood pressure 
Syncope & collapse 183,168 275,767,500 21,252,055 
Orthostatic hypotension 45,931 84,167,001 13,946,523 
Hypotension 10,271 19,179,036 3,180,752 
Acute renal failure 109,491 381,964,643 23,575,006 
Volume depletion 29,194 78,321,892 4,346,054 
Falls & fractures 
Fracture neck of femur 252,059 1,486,141,293 46,531,692 
Head injuries 95,963 156,150,784 23,240,964 
Other fractures 163,258 479,608,842 47,833,068 
Gastrointestinal 
disorders 
Constipation 90,247 201,767,574 8,612,370 
Dysphagia 15,063 40,896,900 5,152,693 
Gastroenteritis 171,988 387,719,186 34,906,804 
Nausea & vomiting 58,531 103,814,381 4,579,029 
Cardiovascular disorders 
Cardiac-related 1,286,168 2,505,795,648 149,445,919 
Stroke 272,006 1,222,495,198 117,306,878 
TIA 72,192 122,932,368 10,699,797 
Genitourinary & renal 
disorders 
Urinary retention 60,585 108,545,215 6,352,785 
Complications with catheter 18,850 35,439,361 1,977,765 
Haematuria 46,186 80,767,214 4,782,350 
Other (All other admissions ) 10,751,808 * * 
Total 15,668,525   
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SUPPLEMENTARY TABLE 2 Non-elective admission count between PD and control group for UTI, pneumonia, hip fractures and other 
fractures excluding ZBDs 
 
 
 
  
Gender Age PD Control Gender Age PD Control 
UTI Hip fractures 
Male 
35 – 44 yrs 7 4,664 
Male 
35 – 44 yrs 1 1,422 
45 – 54 yrs 43 8,442 45 – 54 yrs 8 2,680 
55 – 64 yrs 340 15,391 55 – 64 yrs 100 5,228 
65 – 74 yrs 1,933 30,379 65 – 74 yrs 630 9,783 
75 – 84 yrs 5,415 59,136 75 – 84 yrs 1960 22,643 
> 85 yrs 2,891 60,933 > 85 yrs 1113 25,132 
Female 
35 – 44 yrs 11 12,034 
Female 
35 – 44 yrs 2 591 
45 – 54 yrs 33 14,022 45 – 54 yrs 4 2,394 
55 – 64 yrs 206 17,562 55 – 64 yrs 94 7,636 
65 – 74 yrs 1,119 32,000 65 – 74 yrs 786 19,961 
75 – 84 yrs 3,967 80,087 75 – 84 yrs 2526 63,222 
> 85 yrs 2,843 122,390 > 85 yrs 1551 91,367 
Pneumonia Other fractures 
Male 
35 – 44 yrs 9 18,531 
Male 
35 – 44 yrs 0 7,517 
45 – 54 yrs 78 32,055 45 – 54 yrs 10 8,470 
55 – 64 yrs 582 65,436 55 – 64 yrs 44 7,723 
65 – 74 yrs 3024 119,786 65 – 74 yrs 193 6,865 
75 – 84 yrs 8897 168,447 75 – 84 yrs 450 7,583 
> 85 yrs 5704 136,378 > 85 yrs 197 6,709 
Female 
35 – 44 yrs 19 18,373 
Female 
35 – 44 yrs 2 4,836 
45 – 54 yrs 29 30,618 45 – 54 yrs 2 8,299 
55 – 64 yrs 260 59,256 55 – 64 yrs 70 15,057 
65 – 74 yrs 1330 99,519 65 – 74 yrs 410 19,263 
75 – 84 yrs 4091 158,531 75 – 84 yrs 996 33,902 
> 85 yrs 3581 182,335 > 85 yrs 541 37,034 
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SUPPLEMENTARY TABLE 3 Comparison of non-elective admissions between Parkinson's disease and control groups for UTI, 
pneumonia, hip fractures and other fractures excluding ZBDs 
Gender Age 
PD 
(%) 
Control 
(%) 
Relative 
proportions 
Gender Age 
PD 
(%) 
Control 
(%) 
Relative 
proportions 
UTI Hip fractures 
Male 
35 – 44 yrs 1.97 0.49 4.0 
Male 
35 – 44 yrs 0.28 0.15 1.9 
45 – 54 yrs 2.40 0.74 3.2 45 – 54 yrs 0.45 0.24 1.9 
55 – 64 yrs 4.24 1.19 3.6 55 – 64 yrs 1.25 0.41 3.0 
65 – 74 yrs 6.48 2.00 3.2 65 – 74 yrs 2.11 0.64 3.3 
75 – 84 yrs 8.35 3.58 2.3 75 – 84 yrs 3.02 1.37 2.2 
> 85 yrs 9.19 2.12 4.3 > 85 yrs 3.54 0.88 4.0 
Female 
35 – 44 yrs 4.80 0.62 7.7 
Female 
35 – 44 yrs 0.87 0.03 29.0 
45 – 54 yrs 4.18 1.34 3.1 45 – 54 yrs 0.51 0.23 2.2 
55 – 64 yrs 5.07 1.68 3.0 55 – 64 yrs 2.31 0.73 3.2 
65 – 74 yrs 6.40 2.45 2.6 65 – 74 yrs 4.50 1.53 2.9 
75 – 84 yrs 8.85 4.29 2.1 75 – 84 yrs 5.64 3.38 1.7 
> 85 yrs 9.73 3.52 2.8 > 85 yrs 5.31 2.63 2.0 
Age and sex standardised risk -  6.0 per 100 admissions (95% CI 
5.9, 6.1);  proportional admission ratio – 2.63 (95% CI 2.59, 
2.67, p<0.0001) 
Age and sex standardised risk -  2.8 per 100 admission (95% CI 2.7, 2.8);  
proportional admission ratio – 2.21 (95% CI 2.16, 2.25, p<0.0001) 
 
Pneumonia Other fractures 
Male 
35 – 44 yrs 2.53 1.97 1.3 
Male 
35 – 44 yrs 0.00 0.80 0.0 
45 – 54 yrs 4.36 2.82 1.5 45 – 54 yrs 0.56 0.74 0.8 
55 – 64 yrs 7.25 5.08 1.4 55 – 64 yrs 0.55 0.60 0.9 
65 – 74 yrs 10.14 7.89 1.3 65 – 74 yrs 0.65 0.45 1.4 
75 – 84 yrs 13.72 10.19 1.3 75 – 84 yrs 0.69 0.46 1.5 
> 85 yrs 18.13 4.75 3.8 > 85 yrs 0.63 0.23 2.7 
Female 
35 – 44 yrs 8.30 0.95 8.7 
Female 
35 – 44 yrs 0.87 0.25 3.5 
45 – 54 yrs 3.68 2.94 1.3 45 – 54 yrs 0.25 0.80 0.3 
55 – 64 yrs 6.40 5.67 1.1 55 – 64 yrs 1.72 1.44 1.2 
65 – 74 yrs 7.61 7.61 1.0 65 – 74 yrs 2.35 1.47 1.6 
75 – 84 yrs 9.13 8.48 1.1 75 – 84 yrs 2.22 1.81 1.2 
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> 85 yrs 12.26 5.24 2.3 > 85 yrs 1.85 1.07 1.7 
Age and sex standardised risk -  8.4 per 100 admission (95% CI 
8.3, 8.5);  proportional admission ratio - 1.55 (95% CI 1.53, 1.57, 
p<0.0001) 
Age and sex standardised risk -  1.2 per 100 admission (95% CI 1.1, 1.2);  
proportional admission ratio - 1.45 (95% CI 1.39, 1.50, p<0.0001) 
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SUPPLEMENTARY TABLE 4 Comparison of mean length of stay for non-elective admissions between PD and control group for 
UTI, pneumonia, hip fractures and other fractures excluding ZBDs 
Gender Age PD (Days) Control (Days) Gender Age PD (Days) Control (Days) 
UTI Hip fractures 
Male 
35 – 44 yrs 6 5 
Male 
35 – 44 yrs 12 10 
45 – 54 yrs 9 6 45 – 54 yrs 7 12 
55 – 64 yrs 11 7 55 – 64 yrs 22 15 
65 – 74 yrs 15 8 65 – 74 yrs 25 18 
75 – 84 yrs 16 11 75 – 84 yrs 29 22 
> 85 yrs 17 13 > 85 yrs 28 24 
Female 
35 – 44 yrs 8 4 
Female 
35 – 44 yrs 5 10 
45 – 54 yrs 8 5 45 – 54 yrs 40 11 
55 – 64 yrs 11 7 55 – 64 yrs 20 13 
65 – 74 yrs 14 9 65 – 74 yrs 24 16 
75 – 84 yrs 16 12 75 – 84 yrs 26 20 
> 85 yrs 16 14 > 85 yrs 26 23 
Pneumonia Other fractures 
Male 
35 – 44 yrs 10 6 
Male 
35 – 44 yrs 0 4 
45 – 54 yrs 13 7 45 – 54 yrs 18 5 
55 – 64 yrs 14 8 55 – 64 yrs 15 6 
65 – 74 yrs 15 9 65 – 74 yrs 18 8 
75 – 84 yrs 16 11 75 – 84 yrs 19 13 
> 85 yrs 17 13 > 85 yrs 19 16 
Female 
35 – 44 yrs 6 6 
Female 
35 – 44 yrs 4 4 
45 – 54 yrs 21 6 45 – 54 yrs 7 4 
55 – 64 yrs 14 7 55 – 64 yrs 10 4 
65 – 74 yrs 15 9 65 – 74 yrs 13 6 
75 – 84 yrs 15 12 75 – 84 yrs 18 12 
> 85 yrs 16 13 > 85 yrs 19 16 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
SUPPLEMENTARY TABLE 5 Deaths during admissions* 
Gender Age 
PD Control 
Relative 
proportions Died 
Total 
admissions 
Proportion 
(%)  
Died 
Total 
admissions 
proportion  
(%) 
Male 
35 – 44 yrs 1 650 0.2 6,576 2,407,032 0.3 0.7 
45 – 54 yrs 30 3,463 0.9 16,331 3,334,200 0.5 1.8 
55 – 64 yrs 266 15,585 1.7 40,313 4,463,862 0.9 1.9 
65 – 74 yrs 1,986 49,144 4.0 81,834 5,345,948 1.5 2.7 
75 – 84 yrs 6,749 87,232 7.7 141,343 4,561,930 3.1 2.5 
> 85 yrs 4,454 36,624 12.2 130,592 3,691,986 3.5 3.5 
Total 13,486 192,698 7.0 416,989 23,804,958 1.8 3.9 
Female 
35 – 44 yrs 7 418 1.7 5,590 4,002,933 0.1 17.0 
45 – 54 yrs 15 1,766 0.8 13,533 3,883,641 0.3 2.7 
55 – 64 yrs 133 8,220 1.6 30,387 4,236,542 0.7 2.3 
65 – 74 yrs 806 28,641 2.8 60,118 4,735,830 1.3 2.2 
75 – 84 yrs 3,308 57,364 5.8 132,721 4,461,605 3 1.9 
> 85 yrs 3,190 32,559 9.8 195,904 4,303,665 4.6 2.1 
Total 7,459 128,968 5.8 438,253 25,624,216 1.7 3.4 
Age and sex adjusted mortality risk 4.3 per 100 admissions (95% CI 4.2, 4.3); 
Proportional mortality ratio -  2.46 (95%CI 2.42, 2.49, p<0.0001)  
* Only admissions and deaths occurring within the 4 year study period are included 
 
 
